Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoVector to Commercialize First Biologic Nanoparticle Drug Delivery System

Abstract:
Plant Virus Nanoparticle is Nature's Perfect Vehicle for Targeted Intracellular Cancer Therapeutics

NanoVector to Commercialize First Biologic Nanoparticle Drug Delivery System

Raleigh, NC | Posted on December 3rd, 2008

NanoVector, Inc. announced today that it has licensed the plant virus nanoparticle drug delivery system developed by Professors' Stefan Franzen and Steven Lommel from North Carolina State University. "This is breakaway technology that will finally provide the highly sought after selective targeting of tumors and intracellular delivery of anti-cancer agents for improved efficacy and fewer unpleasant side effects," said Albert Bender, Ph.D., NanoVector CEO. "The plant virus nanoparticle has evolved over millions of years to have several inherent characteristics essential for a successful nanoparticle delivery system and superior to any chemistry based nanoparticle designed and engineered by humans." continued Dr. Bender.

The most important property of the virus is its built-in sensor-actuator system. When the virus carrying the therapeutic agent enters a cell, it senses a change in chemical environment and automatically unloads its cargo. Therefore the highly toxic therapeutic agent is released only in a cell, never in the blood stream as with manmade particles that depend upon capsule degradation or require an external trigger to open the particles for the release of their content. The benefit derived from this feature of the NanoVector nanoparticle is the minimization of the toxic side effects associated with free anti-cancer drugs in the blood stream that attack healthy cells.

A second feature of the plant virus is that its automatic release of cargo is not instantaneous once the virus enters a cell. This allows time for the licensed two-stage targeting in which nuclear importins attached to the nanoparticle guide it into the cell nucleus where it unloads its therapeutic agent, thereby maximizing efficacy and evading the cancer cell defenses. Delivery to the nucleus overcomes multi-drug resistance that occurs with current drug therapies.

Robustly protecting its cargo in very harsh environments is another property of the NanoVector plant virus nanoparticle. Unlike other viruses, the NanoVector plant virus is non-toxic to humans and, without specific cell targeting, will not accumulate in any body organs or otherwise healthy tissue. This makes it the perfect vehicle for targeted intracellular therapeutics.

####

About NanoVector, Inc.
NanoVector is an early stage biopharmaceutical company commercializing targeted intracellular therapeutics. The plant virus nanoparticle drug delivery platform will be used to develop a family of targeted delivery, encapsulated cytotoxic drugs that are currently non cell-selective for the $43B/yr worldwide cancer markets. NanoVector will also form strategic partnerships with pharmaceutical companies for joint development of targeted intracellular therapeutics for a wide range of indications.

NanoVector received a Small Business Research Loan from North Carolina Biotechnology Center and is in the process of raising a $1,000,000 seed round to fund taking the first drug through preclinical toxicity, safety, and stability studies required to submit an Investigational New Drug (IND) application to the FDA.

For more information, please click here

Contacts:
NanoVector, Inc.
Albert Bender, Ph.D.
CEO
919-878-8464

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

Nanomedicine

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Production of Biocompatible Polymers in Iran October 30th, 2014

Amorphous Coordination Polymer Particles as alternative to classical nanoplatforms for nanomedicine October 30th, 2014

'Electronic skin' could improve early breast cancer detection October 29th, 2014

Announcements

Nano Ruffles in Brain Matter: Freiburg researchers decipher the role of nanostructures around brain cells in central nervous system function October 31st, 2014

Gold nanoparticle chains confine light to the nanoscale October 31st, 2014

'Nanomotor lithography' answers call for affordable, simpler device manufacturing October 31st, 2014

Device invented at Johns Hopkins provides up-close look at cancer on the move: Microscopic view of metastasis could give insight about how to keep cancer in check October 31st, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE